Optiscan Imaging (ASX: OIL) Starts US Head and Neck Cancer Study

Optiscan Imaging has started a US head and neck cancer imaging study under a new Research Agreement with Mayo Clinic.

Recruitment is underway for the 35-patient study at Mayo Clinic Rochester. It will assess Optiscan’s InVue and InForm platforms during tumour resections.

The resulting data will support planned US Food and Drug Administration submissions for both devices later in calendar 2026.

Inside the Clinical Study

InVue will capture real-time, in vivo microscopic images inside the surgical cavity following tumour removal. Researchers will examine its performance when assessing surgical margins and visualising tissue.

The study will use intravenous fluorescein sodium contrast agent supplied by Long Grove Pharmaceuticals. This will help researchers evaluate tissue visualisation and potential differentiation between cancerous and healthy structures.

After excision, tissue specimens will undergo ex vivo imaging with the InForm digital pathology platform. Acridine Orange dye will facilitate this part of the imaging process.

Together, the devices span the surgical and pathology workflows. The study will assess their integration while producing complementary imaging data from the same clinical setting.

Mayo Clinic oral and maxillofacial surgeons Kyle Ettinger and Kevin Arce will lead the study.

The Regulatory Read-Through

The main near-term relevance is the study’s connection to Optiscan’s US regulatory program. The company has scheduled FDA submissions for InVue and InForm later in 2026.

Data will come from a US patient population and cover both in vivo and ex vivo imaging. Optiscan expects it to complement evidence from multiple tissue and cancer types.

The company’s published roadmap places both devices at the clinical validation stage. Dossier preparation, submission, regulatory clearance and commercial deployment remain subsequent steps.

Importantly, study initiation does not provide evidence of device performance or regulatory approval. The announcement also gives no completion date, study results, costs or financial terms.

Why Head and Neck Surgery Is Challenging

Head and neck cancers affect areas including the oral cavity, pharynx and larynx. Surgery must balance tumour removal against preserving speech, swallowing and breathing functions.

Around 890,000 new cases and 450,000 deaths occur worldwide each year, according to figures cited by Optiscan. The disease is the seventh most common cancer globally.

The announcement also notes that up to 50% of patients experience recurrence after treatment. That clinical burden explains the focus on visualising surgical margins in real time.

Extending the Platform’s Evidence Base

The study adds another cancer type and surgical setting to Optiscan’s clinical evaluation program. It also tests two products within one connected workflow.

Optiscan is a commercial-stage medical technology company focused on digital pathology and precision surgery. Its technology enables live optical biopsy and single-cell-level imaging.

Successful completion could strengthen clinical evidence supporting the devices in surgery and pathology assessment. However, the current announcement concerns recruitment and evaluation rather than adoption or sales.

The combined workflow could also inform future medical-device, digital-pathology, software and artificial-intelligence applications. Those opportunities remain dependent on study findings and later regulatory progress.